Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
NCT01206309 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
Conditions Studied
Study Locations (14)
New York
- Roswell Park Cancer Institute — Buffalo
- Weill Cornell Medical College — New York
Ohio
- Cleveland Clinic Foundation — Cleveland
- The Ohio State University — Columbus
Arizona
- Mayo Clinic — Scottsdale
California
- Stanford University — Stanford
Florida
- H. Lee Moffitt Cancer Center — Tampa
Massachusetts
- Dana Farber Cancer Institute — Boston
Minnesota
- University of Minnesota — Minneapolis
Missouri
- Washington University St. Louis — St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 911 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-10 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01206309
The ClinicalTrials.gov registry entry for NCT01206309 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 911 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 319 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Graft vs Host Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01206309 reports 14 study locations spanning 12 distinct geographic areas — top geographies include New York, Ohio, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01206309 about?
NCT01206309 is a clinical study titled "Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation". The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
What is the current status of trial NCT01206309?
This trial is currently completed. The enrollment target is 911 participants. The study started on 2011-03. Estimated completion is 2016-10.
What conditions does trial NCT01206309 study?
This clinical trial studies the following conditions: Graft vs Host Disease, Bronchiolitis Obliterans, Cutaneous Sclerosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT01206309?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 319 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01206309 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.